About liver diseases
Liver diseases are of
different types such as hepatitis, liver cancer, non-alcoholic fatty
liver disease, and liver cirrhosis. Hepatitis is the largest segment
among these diseases, of which hepatitis C is the biggest and fastest
growing segment. The liver diseases caused by viral infections,
alcoholism, obesity, diabetes, among many other reasons. Some of the
diseases are not curable such as liver cirrhosis or non-alcoholic
fatty liver disease, and are usually not diagnosed early. This leads
to the substantial damage of the liver, which proves to be
life-threatening. Some types of hepatitis are preventable or
treatable by using vaccines and indicated drugs.
Technavio's analysts forecast
the global liver diseases therapeutics market to grow at a CAGR of
15.61% over the period 2014-2019.
Download Sample copy of
this Report @
http://www.marketresearchreports.biz/sample/sample/386540
Covered in this report
This report covers the present
scenario and the growth prospects of the global liver diseases
therapeutics market for 2015-2019. To calculate the market size, the
report considers revenue generated from the sales of various
off-label and branded drugs and the expected launch of drug
candidates intended to be used in the treatment of liver diseases.
Based on disease indication,
the market is segmented as follows:
- Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis)
- Liver cirrhosis
- Liver cancer
- Hepatitis (Hepatitis A, B, and C)
This report includes a
discussion of the market in the following three regions:
Americas: The major countries
focused in the Americas are the US, Canada, Mexico, and Brazil
EMEA: The major countries in
this region are the UK, Germany, Italy, France, Spain and Middle
Eastern and African countries such as Israel, South Africa, Egypt,
Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
APAC: The major countries in
this region are Japan, China, Australia, Singapore, South Korea, and
India.
Technavio's report, Global
Liver Diseases Therapeutics Market 2015-2019, has been prepared based
on an in-depth market analysis with inputs from industry experts. The
report covers the landscape of the global liver diseases therapeutics
market and its growth prospects in the coming years. The report
includes a discussion of the key vendors operating in this market.
Key regions
- Americas
- APAC
- EMEA
Key vendors
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
Other prominent vendors
- Achillion Pharmaceuticals
- AstraZeneca
- obira Therapeutics
- VBL Therapeutics
- Verva Pharmaceuticals
- Virobay
- Zafgen
Key market driver :
Increased prevalence of liver
diseases
Key market challenge :
Multiple patent expiries
Key market trend : Growing
public awareness
Table
of Content :
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top vendor offerings
PART 03: Market research
methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Five forces analysis
Browse Press Releases by
Prweb :
About us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact us:
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment